Focused On-demand Library for Integrator complex subunit 7

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

Our top-notch dedicated system is used to design specialised libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.

Several key aspects differentiate our library:

Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

Q9NVH2

UPID:

INT7_HUMAN

Alternative names:

Alternative UPACC:

Q9NVH2; B4DLZ6; B7WNP6; B7WPB6; Q8N4K7; Q8WUH5; Q9H9V3; Q9NVU5; Q9UFC6; Q9UFM3

Background:

Integrator complex subunit 7 plays a pivotal role in the transcription and processing of small nuclear RNAs (snRNAs) U1 and U2, essential components of the spliceosome. It is part of the Integrator complex, which is crucial for snRNA gene expression and is linked to the RNA polymerase II. This protein also contributes to the DNA damage response signaling, highlighting its importance in maintaining genomic integrity.

Therapeutic significance:

Understanding the role of Integrator complex subunit 7 could open doors to potential therapeutic strategies. Its involvement in crucial cellular processes such as snRNA transcription, processing, and DNA damage response, positions it as a key target for drug discovery efforts aimed at treating diseases linked to genetic dysregulation and cellular damage.